医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Kubota Vision Completes POC Clinical Study Using Wearable Myopia Control Device Based on Kubota Glasses Technology

2020年08月26日 AM12:00
このエントリーをはてなブックマークに追加


 

SEATTLE

Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the successful completion of a proof-of-concept (POC) clinical study using a wearable myopia control device based on Kubota Glasses technology. This study confirmed that the changes in axial length from baseline in the test eye vs. control eye, previously seen utilizing a bench top device that projected defocused images on the peripheral retina, can be replicated with a wearable device.

The study monitored effects of projected peripheral defocus on ocular biometrics, including axial length, using a wearable device in 25 subjects aged 18 to 35 years at the Manhattan Vision Associates / Institute for Vision Research (MVA), New York in the U.S. MVA is a prestigious and well-known vision care institute in New York which has conducted many successful clinical trials for contact lenses and eyeglasses. A wearable prototype is expected to be available by the end of 2020 and anticipated to launch as a market-ready device in 2021. For more information about this study, please refer to https://clinicaltrials.gov/ct2/show/NCT04415684 (ClinicalTrials.gov Identifier: NCT04415684).

Myopia, or nearsightedness, is a refractive vision disorder which causes blurred sight at a distance. It occurs when the length of the eye (known as axial length) is too great; myopia progresses as axial length increases with age, until the early 20s. Myopia currently affects 2.56 billion people worldwide and is projected to affect 3.4 billion people by 2030, if current trends remain unchanged.*1 Myopia increases the risk of developing sight-threatening diseases such as myopic maculopathy, retinal detachment, and glaucoma – making a measurable impact on society.*2 Today children in East Asia, including Japan, China, Hong Kong, Taiwan, South Korea, and Singapore, develop myopia at a high rate; for example, 96.5% of 19-year-old males suffer from myopia in Seoul.*3 Myopia also affects over 40% of individuals over the age of 12 years in the U.S.*4

Ryo Kubota, MD, PhD, Chairman, President and CEO of Kubota Vision Inc., stated, “It is another great achievement that this POC study using a wearable device demonstrated the same efficacy as a bench top device. We will continue our effort to produce more scientific evidence on Kubota Glasses technology through further clinical studies so that our wearable myopia device will soon become available to people in need.”

*1 Report of the Joint World Health Organization–Brien Holden Vision Institute, University of New South Wales, Sydney, Australia. The impact of myopia and high myopia. 16–18 March 2015. https://www.who.int/blindness/causes/MyopiaReportforWeb.pdf.

*2 Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012 Nov;31(6):622-60

*3 Dolin E. The myopia boom. Nature 2015 Mar 19;519(7543):276-8

*4 Prevalence. International Myopia Institute. https://www.myopiainstitute.org/prevalence.html. Accessed May 15, 2020.

About Kubota Glasses Technology

Kubota Glasses technology works to reduce the increase in axial length associated with myopia by projecting myopically-defocused virtual images generated using micro-LEDS on the peripheral visual field to actively stimulate the retina. Using this method, a clinical study utilizing a bench top device demonstrated that axial length decreases in the test eye compared to the control eye as the stimulus is applied. Passive stimulation using myopic defocus is already in use in an FDA-approved contact lens. Kubota Glasses technology leverages nanotechnology in its electronic glasses-based device and seeks to reduce the progression of myopia by actively stimulating the retina for shorter periods while maintaining central vision and not affecting daily activities. The company is planning to submit the full data for scientific publication.

About Kubota Vision Inc.

Kubota Vision Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group’s development pipeline includes drug candidates for the treatment of diabetic retinopathy, Stargardt disease, and optogenetics-based gene therapy for the treatment of retinitis pigmentosa. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients, and wearable device for myopia control. https://www.kubotavision.com/; https://www.kubotaholdings.co.jp/en/

Cautionary Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include statements regarding our expectations related to our development plans and ability to successfully develop and commercialize our product candidates and the potential efficacy, future development plans and commercial potential of our product candidates. These statements are based on current assumptions that involve risks, uncertainties and other factors that could cause the actual results, events or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our investigational product candidates may not demonstrate the expected safety and efficacy; our pre-clinical development efforts may not yield additional product candidates; any of our or our collaborators’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; our clinical trials could be delayed; new developments in the intensely competitive ophthalmic pharmaceutical market may require changes in our clinical trial plans or limit the potential benefits of our investigational product candidates; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. For a detailed discussion of the foregoing risks and other risk factors, please refer to our filings with the Securities and Exchange Commission, which are available on Kubota Pharmaceutical Holdings (Kubota Vision’s parent company) investor relations website (https://www.kubotaholdings.co.jp/en/ir/) and on the SEC’s website (http://www.sec.gov).

“Kubota Vision”, the Kubota Vision logo and “Kubota” are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005309/en/

CONTACT

Media and Investor Relations Contact:

Hiroki Maekawa

Chief Financial Officer

Phone: +81-3-6550-8928

Email: pr@kubotaholdings.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda to Divest TachoSil® to Corza Health for €350 Million
  • 新たな研究:ハンドドライヤーによる手の乾燥はペーパータオルと同じくらい衛生的
  • Body Fit Training PTY LTD Sues to Invalidate F45 Training PTY LTD’s U.S. Patents
  • Singapore and Apple Partner on National Health Initiative Using Apple Watch
  • 最新研究:干手机与用纸巾擦干双手一样卫生